BeOne Sponsored Breakfast Symposium: Optimising outcomes in CLL: From treatment selection to ongoing patient support
| Monday, October 19, 2026 |
| 7:00 AM - 8:15 AM |
| 516 |
Details
Choosing the Right Therapy for Patients with CLL: A Practical Approach to Personalised Treatment Selection
In Australia, the treatment landscape for CLL has evolved rapidly, with clinicians now able to choose from multiple targeted therapies across both treatment-naïve and relapsed/refractory settings. This presentation will explore a practical, patient-centred approach to treatment selection, drawing on current CLL guidelines and the latest clinical evidence. Key considerations will include efficacy and safety of available treatment options, as well as patient-specific factors. Through the lens of real-world clinical decision-making, the session will provide a practical framework to support personalised treatment selection in contemporary CLL practice.
Supporting Patients Through CLL Therapy: Practical Strategies for Supportive Care and Infection Prevention
With advances in targeted therapies transforming outcomes in CLL, supportive care has become a critical component of patient management. This presentation will review contemporary approaches to infection prevention and supportive care throughout the treatment journey, including risk assessment, immunoglobulin replacement for hypogammaglobulinaemia, practical management considerations during targeted therapy, and strategies to enhance patient and clinician education.
Speaker
Prof Stephen Opat
Program Medical Director, Cancer Service
Monash Health
Choosing the Right Therapy for Patients with CLL: A Practical Approach to Personalised Treatment Selection
7:00 AM - 8:15 AMBiography
Stephen Opat is an internationally renowned expert in CLL and lymphoma ranked in the top 1% of published authors. He serves as Cancer Program director at Monash Health, research lead CLL/indolent lymphoma, Chair, CLL Scientific Working Party of ALLG and founder/chair of the Australasian Lymphoma and Related Diseases Registry.
Prof Robert Weinkove
Clinical Director
Malaghan Institute Of Medical Research
Supporting Patients Through CLL Therapy: Practical Strategies for Supportive Care and Infection Prevention
7:00 AM - 8:15 AMBiography
Rob Weinkove is Clinical Director at the Malaghan Institute of Medical Research, a Haematologist at Health New Zealand, and Honorary Professor at the University of Auckland. After studying medicine at the University of Cambridge and Kings College London, he trained in clinical haematology in London and in Hannover, and undertook a PhD in immunology at the University of Otago.
Prof Weinkove leads a clinical and translational chimeric antigen receptor (CAR) T-cell programme at the Malaghan Institute. He is also an active member of the Australasian Leukaemia & Lymphoma Group, contributing to co-operative group and clinical trials in the fields of B-cell malignancies and prevention of infection in the immunocompromised.
